{"id":"NCT00225017","sponsor":"Northwestern University","briefTitle":"Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study","officialTitle":"Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study: Endothelial Function in HIV-Infected Subjects Switched to an Atazanavir Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2005-09-23","resultsPosted":"2012-08-02","lastUpdate":"2012-08-02"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infection","Hyperlipidemia"],"interventions":[{"type":"DRUG","name":"Atazanavir","otherNames":["Reyataz"]},{"type":"DRUG","name":"current antiretroviral regimen","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the change in brachial artery reactivity in HIV-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen","primaryOutcome":{"measure":"Percentage Change in Brachial Artery Flow Mediated (FMD) Vasodilation Between Arms From Baseline to Week 24","timeFrame":"Baseline to week 24","effectByArm":[{"arm":"Atazanavir Switch","deltaMin":-1.14,"sd":null},{"arm":"Control (Continue Protease Inhibitor)","deltaMin":0.25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.601"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":7,"countries":["United States","Argentina","Italy"]},"refs":{"pmids":["19952712"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":[]}}